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RESEARCH ARTICLE
Oxytocin receptor is regulated by Peg3
Wesley D. Frey1, Kaustubh Sharma1, Terri L. Cain1, Katsuhiko Nishimori2,
Ryoichi Teruyama1, Joomyeong Kim1*
1 Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, United States of America,




Mouse Peg3 encodes a DNA-binding protein involved in the milk letdown process. In the
current study, we tested whether PEG3 controls the expression of the oxytocin receptor
gene. According to the results, PEG3 directly binds to a genomic region within the 3rd exon
of Oxtr, which contains a DNA-binding motif for PEG3. In nursing female mice, removal of
PEG3 resulted in the increased expression of Oxtr in mammary epithelial cells and also in
the hypothalamus. This suggests a repressor role of PEG3 in the expression of Oxtr in
these tissues. Overall, this study suggests that Peg3 may function as a direct transcriptional
regulator for Oxtr expression that acts to moderate the milk letdown process.
Introduction
Peg3 (Paternally Expressed Gene 3) is an imprinted gene localized in proximal mouse chromo-
some 7/human chromosome 19q13.4 [1–3]. This gene encodes a DNA-binding protein with
12 C2H2 zinc finger motifs known to bind to a large number of genomic targets [4–7]. The list
of known downstream genes includes Pgm2l1, H19, Msl1 and Msl3. PEG3 also contains a
KRAB-A domain, thus is predicted to be a transcriptional repressor through its interaction
with KAP1 [8]. This predicted repression function has been further confirmed through the
observation that the expression levels of its downstream genes are usually up-regulated in the
tissues of the mouse mutant models targeting Peg3 [6, 7]. According to the results from mouse
knockout (KO) models, Peg3 is also involved in controlling fetal growth rates and maternal-
caring behaviors [9–13]. However, the detailed mechanism by which Peg3 is involved in these
biological pathways is not well understood.
In murine Peg3-KO studies, both nursing females and pups tend to have a problem in milk
provision, subsequently causing reduced growth rates in the pups lacking Peg3 [9–13]. In pla-
cental mammals, milk letdown is mediated through oxytocin circuitry involving the peptide
hormone oxytocin (Oxt) and its receptor, oxytocin receptor (Oxtr) [14, 15]. Oxytocin is pro-
duced in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothala-
mus. Axonal projections of these nuclei lead to the posterior pituitary gland, where oxytocin is
released into the bloodstream, and exerts its effects through binding to oxytocin receptors
present in the target tissues, including uterus, ovary and mammary gland [14, 15]. In a prior
mutant model of Peg3, reduced numbers of Oxt-expressing neurons were initially observed,
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which was then thought to be a main cause for the milk provision problem [9]. However, this
has been later argued by two independent studies reporting that the mutations did not cause
any change in the numbers of Oxt-immunoreactive neurons in the hypothalamus [13, 16, 17].
Nevertheless, subsequent experiments confirmed again the presence of the milk provision
problem in several Peg3-KO models, and further substantiated that this defect was more pro-
nounced through the conditional mutation of Peg3 in the mammary gland than in the hypo-
thalamus [12]. This further suggests that Peg3 might play more significant roles in the
mammary gland than in the hypothalamus for the milk provision process [12]. Consistent
with this, Peg3 is expressed not only in the hypothalamus but also in the other tissues, includ-
ing placenta, uterus, testis, ovary, and mammary gland [1–3].
Oxtr is also known to be widely expressed in various tissues, including the ovary, uterus,
brain and mammary gland, whereas Oxt is mainly expressed in the hypothalamus. Yet, condi-
tional KO of Peg3 in the mammary gland exhibited similar defects as those observed from the
earlier Peg3-KO models, suggesting that Peg3 may be involved in the oxytocin circuitry not
only through Oxt in the hypothalamus but also through Oxtr in the mammary gland. This pos-
sibility was tested in the current study by performing a series of experiments. The results sug-
gest that PEG3 may function as a transcriptional repressor for the expression of Oxtr.
Results
PEG3 binding to the mouse Oxtr locus
The predicted protein function of PEG3 has been previously tested through performing several
ChIP-seq (Chromatin ImmunoPrecipitation-sequencing) experiments [4–6]. For these experi-
ments, we time-mated C57BL/6J females with Peg3CoKO/+ males, and the subsequent 14.5-dpc
(day postcoitum) embryos were used for preparing a set of mouse embryonic fibroblast (MEF)
cells, Peg3+/+ (WT) and Peg3+/CoKO (KO) [6]. The chromatin prepared from this set of MEFs
were individually immunoprecipitated with anti-PEG3 antibody, and subsequently analyzed
with Next Generation Sequencing. This survey identified an initial set of 16 downstream
genes, which have been recently published [6]. We further inspected the output by manually
scanning the entire set of chromosomes for potential downstream genes. This series of manual
inspections identified an additional set of potential genomic targets, including the Oxtr locus
(Fig 1A). At the Oxtr locus, a ChIP-seq peak was found within the 3rd exon, which spans a
225-bp genomic region (chr6:112,488,870–112,489,904 in mm10). It is also relevant to note
that we were unable to find any significant ChIP-seq peak around the Oxt locus (S1 File).
Potential binding of PEG3 to the identified region of the Oxtr locus was further tested
through performing independent ChIP experiments (Fig 1B). Several sets of the chromatin
from MEFs and brains of WT and KO were immunoprecipitated again with the antibody
against PEG3. As shown in Fig 1B, the levels of enrichment by the antibody were higher in
WT than those from KO-MEF cells, confirming the binding of PEG3 to the target region of
the Oxtr locus. This was also the case for the brain, which displayed higher levels of enrichment
in the WT than in the KO samples. Thus, this series of ChIP experiments confirmed that the
identified region is indeed bound by PEG3.
According to previous studies, PEG3 is known to bind to genomic regions with the follow-
ing consensus DNA motif: 5'-N-N-G-G-[C/G]-N-[C/G-]-T-3'with N indicating any
base [5]. Thus, we scanned the 20-kb genomic region of the Oxtr locus to identify potential
genomic regions with this motif. This manual scanning also focused on the genomic regions
with potential regulatory function based on their histone modification and DNA methylation
profiles. Oxtr is known to be expressed in cerebellum and uterus, thus we selected three geno-
mic regions that are protected from DNA methylation in these tissues. From these regions
Peg3 control on Oxtr
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indicated with blue bars in Fig 2A, we have identified 5 potential binding sites, BS1 through 5.
PEG3 binding to these potential binding sites was subsequently tested through a series of
EMSAs (Electrophoretic Mobility Shift Assays) (Fig 2B). For this series of analyses, we used a
previously characterized binding site from the Pgm2l1 locus as a probe [4, 5], and nuclear
extracts prepared from mouse brains. Binding of PEG3 to the P32-labeled Pgm2l1 oligonucleo-
tide duplex was competed against each candidate DNA-binding site. The results indicated that
two candidate sites, BS2 and BS5, did not compete at all, suggesting that these two regions may
not contain a DNA-binding site for PEG3. In contrast, the three remaining binding sites, BS1,
BS3, and BS4, competed well against the Pgm2l1 probe, suggesting that these regions may have
high-affinity DNA-binding sites for PEG3. In particular, BS4 is located within the target region
that had already been identified through independent ChIP-seq experiments (Fig 1). Thus,
this series of analyses confirmed that the Oxtr locus has several potential binding sites for
PEG3, and that one of these binding sites is indeed bound by PEG3 in vivo.
Mutational effects of Peg3 and Oxtr on animal survival and growth rates
Potential involvement of Peg3 in the expression and function of Oxtr was further tested
through crossing two mutant mouse lines, OxtrVenus/+ and Peg3CoKO/+ (Fig 3A). Both mutant
alleles were generated using similar knock-in (KI) and knock-out (KO) strategies [11, 18]. The
3rd exon of Oxtr makes up the majority of the coding region (amino acid position 1–306 of the
Fig 1. PEG3 binding to the mouse Oxtr locus. (A) The 40-kb genomic region surrounding the Oxtr locus is shown
using the UCSC genome browser. The black boxes indicate the 4 exons of Oxtr, while the arrows indicate the
transcriptional direction of Oxtr. The identified potential target region of PEG3 is also indicated with a vertical thick
line (Oxtr-ChIP-BS4). Processed ChIP-seq results from WT and KO MEF cells (WT_Peg3.bw and KO_Peg3.bw) were
uploaded onto the genome browser to show the enrichment levels by PEG3-ChIP. (B) Individual ChIP experiments.
The chromatin from MEF and adult brains were immunoprecipitated with anti-PEG3 antibody. The subsequent DNA
set, including Input, Negative without any antibody (Neg), the immunoprecipitated DNA with anti-PEG3 antibody
(PEG3 IP), were used as templates for a fixed number of PCR cycle to test the in vivo binding of PEG3 to the target
region (ChIP-BS4). The relative enrichment levels against Input were measured with qPCR experiments and further
compared between Neg and PEG3 IP. Asterisks represent statistical significance of the observed differences between
Neg and PEG3 IP (, p value< 0.05).
https://doi.org/10.1371/journal.pone.0202476.g001
Peg3 control on Oxtr
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388 amino-acid-long ORF), which has been replaced by an exogenous cassette expressing the
reporter construct Venus. Thus, the mutant allele expresses the reporter protein instead of the
endogenous gene product, oxytocin receptor. In the case of the Peg3 locus, another cassette
Fig 2. Potential DNA-binding sites of PEG3 within the Oxtr locus. (A) The 20-kb genomic region of Oxtr was
scanned with the consensus DNA-binding motif of PEG3, 5’-N-N-G-G-[C/G]-N-[C/G]-T with N being any nucleotide
bases, identifying 5 potential binding sites, BS1-BS5. These binding sites are localized within three genomic regions
with DNA hypomethylation, which are indicated with blue bars. (B) Competitive EMSA (Electrophoretic Mobility
Shift Assay). The P32-radiolabeled oligonucleotide duplex probe derived from the Pgm2l1 locus was mixed with mouse
brain nuclear extracts (lane 2), and further competed against a set of 5 potential binding sites (lane 3–7). The relative
ratio of the labeled Pgm2l1 probe to BS1—BS5 oligonucleotide duplexes was 1 to 200. The sequences of the
oligonucleotides used for this assay are shown on right. The potential binding sites are indicated with either underlines
or red fonts. The sites with red font indicate the confirmed DNA-binding sites through EMSA, whereas the sites with
underlines indicate the predicted but unconfirmed sites. The bold-typed nucleotide bases within each site represent the
critical bases for PEG3 binding.
https://doi.org/10.1371/journal.pone.0202476.g002
Fig 3. Schematic representations of mutant alleles and breeding schemes. (A) Targeted alleles of Oxtrvenus and
Peg3CoKO. The 3rd exon of Oxtr has been replaced by an exogenous construct expressing the reporter Venus, thus the
endogenous locus of Oxtr expresses the reporter Venus instead of the endogenous gene product, oxytocin receptor. In
the case of Peg3CoKO, the 5th intron of Peg3 has been inserted with an expression cassette containing β-Gal and NeoR
along with Poly(A) signals, thus causing transcriptional truncation and subsequent loss of the PEG protein. (B)
Breeding scheme. Female heterozygotes for Oxtrvenus/+ were crossed with male heterozygotes for Peg3CoKO/+. The
subsequent breeding results were presented with individual litter sizes, and also with a table summarizing the
frequency of the four genotypes on right.
https://doi.org/10.1371/journal.pone.0202476.g003
Peg3 control on Oxtr
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expressing β-Galactosidase (β-Gal) and Neomycin Resistance (NeoR) was inserted into the 5th
intron of Peg3. In this mutant model, two sets of Poly(A) signals included in the expression
cassette cause transcriptional truncation for the endogenous gene, thus resulting in the
removal of PEG3 protein in the entire body [11, 12]. Since Peg3 is expressed only from the
paternal allele as an imprinted gene, paternal transmission of the mutant allele derives its phe-
notypic outcomes, such as reduced growth rates and defects in maternal-caring behaviors.
As a feasibility test, male heterozygotes for Peg3CoKO/+ were bred with female heterozygotes
for OxtrVenus/+, deriving 10 litters of 78 pups (Fig 3B). The average litter size, 7.8, appeared to
be normal given the genetic background of the two mutant strains, C57BL/6J. The observed
frequency of the four genotypes among the pups were also overall similar to those predicted
based on mendelian inheritance pattern. Although the frequency of the pups with double het-
erozygote, OxtrVenus/+; Peg3+/CoKO, was slightly smaller than the expected, 16 versus 19.5, there
was no statistical significance. Thus, this suggests that the pups with the four genotypes are all
viable without any major phenotypic consequence. According to previous studies, the paternal
transmission of Peg3CoKO/+ has been shown to cause reduced body size among the mutant
pups [9–13]. Consistent with this, we also observed reduced body weights among the two
groups of the pups, the first group (Oxtr+/+; Peg3+/CoKO) and the second group (OxtrVenus/+;
Peg3+/CoKO). However, we have not observed any weight difference between these two geno-
types, indicating that the mutation on Oxtr may not have any additional effect on the reduced
growth rates of the animals that had already been impacted by the mutation on Peg3.
Mutational effects of Peg3 on the expression of Oxtr in the mammary gland
The females generated from the breeding experiments were also used to examine the muta-
tional effects of Peg3 on the expression levels and patterns of Oxtr (Fig 4 and Fig 5). For this
series of analyses, we focused on the two major organs that are involved in milk letdown, the
mammary gland and hypothalamus [14, 15]. The tissues were also harvested from the dams at
one day postpartum, since this time-point should be critical for establishing the milk letdown
process in the dams. We set up several sets of breeding pairs with each housing one wild-type
male along with two female littermates with the following genotypes: OxtrVenus/+; Peg3+/+ and
OxtrVenus/+; Peg3+/CoKO. These two types of females will be simply referred to as ‘WT’ and ‘KO’
hereafter based on the genotype of Peg3, respectively. At one day postpartum, the mammary
glands were harvested from the two females, WT and KO, and the harvested tissues were fixed,
and then used for inspecting the spatial expression pattern of Oxtr (Fig 4A). Overall, we
observed a higher density of Venus-positive (Venus+) cells lining the mammary ducts as well
as an increase in Venus+ cells along the basal region of cross-sectioned mammary ductal struc-
tures in KO than in WT samples (Fig 4A). To further follow up this observation, another set of
the mammary glands were harvested from one-day-postpartum female littermates with the fol-
lowing genotypes: Oxtr+/+; Peg3+/+ (WT) and Oxtr+/+; Peg3+/CoKO (KO). These mammary
glands were used for further isolating mammary epithelial cells (MECs), which were used for
isolating total RNA and subsequent cDNA synthesis. This set of cDNA was then used for
another series of expression analyses involving qRT-PCR (Fig 4B). As expected, the expression
levels of Peg3 were significantly down-regulated in the KO sample compared to the WT sam-
ple. This was also the case for another imprinted gene Zim1 (Zinc finger gene 1 imprinted)
and Ghrh (Growth hormone-releasing hormone). In the case of Esr1 (Estrogen receptor
alpha), there was no difference between WT and KO. In contrast, the expression levels of both
Oxtr and Oxt were up-regulated in the KO sample, 1.4-fold and 2.1-fold, respectively. The
observed up-regulation of Oxtr appeared to be consistent with the greater density of Venus+
signals detected from the KO sample (Fig 4A). Thus, this series of analyses concluded that the
Peg3 control on Oxtr
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expression levels of Oxtr were up-regulated in the mammary gland of the KO sample, particu-
larly in the basal region of mammary epithelial cells.
Mutational effects of Peg3 on the expression of Oxtr in the hypothalamus
We also performed a similar series of expression analyses using the hypothalamus that had
been harvested from the same sets of the females with the two genotypes, WT and KO (Fig 5).
For this series of analyses, the harvested brains were first fixed, sectioned and finally immunos-
tained with the following antibodies: anti-OXT and anti-PEG3 antibodies. The expression of
Oxtr was monitored again through the signal of the reporter Venus. As expected, the expres-
sion of Peg3 was not detectable at all throughout the entire area of the hypothalamus in the KO
sample. On the other hand, the spatial expression patterns of Oxtr were quite different between
WT and KO samples. In the WT sample, the expression of Oxtr was mainly detected from the
neuronal cells that are localized immediately adjacent to the 3rd ventricle column. In contrast,
Fig 4. Up-regulation of Oxtr in the mammary gland of nursing females with Peg3+/CoKO. (A) At one day
postpartum, a set of mammary glands were harvested from the following two females: OxtrVenus/+; Peg3+/+ (WT) and
OxtrVenus/+; Peg3+/CoKO (KO). The spatial expression patterns of Oxtr were monitored through the signal of the reporter
Venus, and the intensity of signals were also compared between WT and KO. The top panels represent the excretory
ducts, while the bottom panels show the secretory acini of the mammary gland of the WT and KO mice. Lining
epithelial cells show higher levels of Oxtr immunofluorescence in KO than in WT. The scale bars for both panels are
20 μm. (B) qRT-PCR analyses. Total RNA was isolated from the mammary epithelial cells of female littermates with
the following genotypes: Oxtr+/+; Peg3+/+ (WT) and Oxtr+/+; Peg3+/CoKO (KO). These RNA were used for cDNA
synthesis, which were subsequently used for qRT-PCR analyses. The expression levels of each gene were compared
between WT and KO, and the observed differences were presented with statistical significance (, p<0.01 and ,
p< 0.001).
https://doi.org/10.1371/journal.pone.0202476.g004
Peg3 control on Oxtr
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the expression of Oxtr in the KO sample was detected from the neuronal cells that are localized
in the much broader region of the hypothalamus, suggesting that the mutation on Peg3 may
result in an ectopic expression of Oxtr within the hypothalamus. A series of sections derived
from the different areas of the hypothalamus were also inspected, showing similar ectopic
expression of Oxtr (S2 File). In the case of Oxt, we have not detected any significant difference
between WT and KO samples in terms of its spatial expression pattern (S3 File).
We also performed a series of qRT-PCR to measure the expression level differences of sev-
eral genes between Oxtr+/+; Peg3+/+ (WT) and Oxtr+/+; Peg3+/CoKO (KO) samples (Fig 5B).
According to the results, the expression levels of Peg3 were not detectable in KO, consistent
with the results from previous studies [11, 12]. The expression levels of the three genes, includ-
ing Zim1, Ghrh, and Esr1, showed no major difference between WT and KO samples. On the
other hand, the expression levels of Oxtr and Oxt were similarly up-regulated in the KO sample
Fig 5. Up-regulation of Oxtr in the hypothalamus of nursing females with Peg3+/CoKO. (A) At one day postpartum,
a set of brains were harvested from the following two females: OxtrVenus/+; Peg3+/+ (WT) and OxtrVenus/+; Peg3+/CoKO
(KO). The harvested brains were fixed, sectioned and immunostained with anti-OXT antibody (blue) and anti-PEG
antibody (red). The expression of Oxtr was monitored through the signal of the reporter Venus (green). The top panels
represent a low power view of the hypothalamic region, while the bottom panels show a high power view of the boxed
regions on top panels. Oxtr-Venus+ cells were localized along the 3rd ventricle and almost all co-localized with Peg3 in
WT mice. Oxtr-Venus expression in KO mice was much broader and extended into the medial preoptic area. The scale
bars for top and bottom panels are 0.5 mm and 200 μm, respectively. AC: Anterior Commisure, 3V: 3rd Ventricle,
MPOA: Medial PreOptic Area. (B) qRT-PCR analyses. Total RNA was isolated from the hypothalamus of female
littermates with the following genotypes: Oxtr+/+; Peg3+/+ (WT) and Oxtr+/+; Peg3+/CoKO (KO). These RNA were used
for cDNA synthesis, which were then used for qRT-PCR analyses. The expression levels of each gene were compared
between WT and KO, and the observed differences were presented with statistical significance (, p<0.01 and ,
p< 0.001).
https://doi.org/10.1371/journal.pone.0202476.g005
Peg3 control on Oxtr
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compared to those of the WT sample. The observed up-regulation of Oxtr appeared to agree
with the ectopic expression pattern detected through the immunostaining (Fig 5A). This series
of analyses were repeated three times using three biological replicates. Thus, three independent
trials with two different methods confirmed similar up-regulation of Oxtr in the KO sample.
Overall, this series of analyses demonstrated that the mutation on Peg3 results in the up-regu-
lation of Oxtr in the hypothalamus, which is also similar to the outcome observed in the mam-
mary gland.
Discussion
In the current study, we characterized the in vivo binding of PEG3 to a genomic target that is
located within the 3rd exon of the mouse Oxtr locus. Also, the expression analyses using a
combination of two mutant mouse models, Venus and CoKO, further demonstrated that
removal of PEG3 resulted in the up-regulation of Oxtr in mammary epithelial cells and in the
hypothalamus. Thus, this suggests that Peg3 may play roles as a transcriptional regulator for
the expression of Oxtr.
The results presented here demonstrated that PEG3 may directly control the expression of
Oxtr, as a DNA-binding protein (Fig 1 and Fig 2). This also agrees with the previous studies
that PEG3 functions as a DNA-binding protein controlling the expression of several down-
stream genes, including Pgm2l1, H19, Msl1 and Msl3 [4–7]. PEG3 has been predicted to be a
transcriptional repressor, since the known downstream genes tend to be up-regulated in the
mutant samples lacking PEG3 [6, 7]. This turned out to be the case for Oxtr. In the mammary
gland, the KO sample displayed 1.4-fold up-regulation of Oxtr based on the results from
qRT-PCR, and also exhibited much more dense signals within the location of mammary epi-
thelial cells (Fig 4A). In the hypothalamus, the overall expression levels of Oxtr were also
2-fold up-regulated in the KO sample. Interestingly, the immunostaining showed that the neu-
ronal cells localized in the broader region adjacent to the 3rd ventricle ectopically expressed
Oxtr in the KO sample. A similar observation was also observed from the previous study that
several placenta-specific gene families are ectopically de-repressed in the hypothalamus of the
mutant mice [11]. In that regard, it is also interesting to note that Peg3 is known to be
expressed more preferentially in the vasopressinergic neurons than in the oxytocinergic neu-
rons in the hypothalamus of rats [18]. If this is the case, the observed up-regulation of Oxt
might also be an outcome of the ectopic expression in the KO model, although we have not
been able to confirm this possibility (S3 File). Thus, PEG3 may play a transcriptional repressor
role not only for the cells that already express Oxtr, such as the epithelial cells in the mammary
gland, but also for the cells that do not usually express Oxtr, as seen in the neuronal cells in the
hypothalamus. Overall, the current study clearly demonstrated that PEG3 functions as a tran-
scriptional repressor for Oxtr, and further suggests that this repressor function of Peg3 may be
cell type- and context-dependent.
Several mutant models targeting Peg3 are known to have defects in the milk letdown pro-
cess, and these defects have been, so far, believed to be associated with a loss of OXT protein
levels [9–12]. Yet, the current study indicated that the mutant animals lacking PEG3 have
increased levels of Oxtr and Oxt (Fig 4 and Fig 5). It is somewhat enigmatic how the up-regu-
lated oxytocin circuitry might cause defects in the milk letdown process. Two scenarios are
possible. First, the relative amount of OXTR and OXT to the other proteins may be optimized
and tightly controlled as part of some signaling pathways. In this case, the excessive amount of
OXTR could have a diluting effect on the downstream proteins that are involved in these sig-
naling pathways, thus causing a defect in the milk letdown process. Second, it is also feasible to
predict that the hormone OXT might be produced just sufficient for the cells participating in
Peg3 control on Oxtr
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the oxytocin circuitry. In this situation, if many unrelated cells happen to also express Oxtr due
to its de-repression, this might cause a similar diluting effect on the downstream proteins
involved in the signaling pathways. This is feasible, since Oxtr was found to be ectopically
expressed in the neuronal cells within the hypothalamus of the KO sample (Fig 5A). Overall,
although very speculative at the moment, it should be very interesting to investigate these pos-
sibilities in the near future. On a separate note, it is relevant to note that the expression of Oxt
and Oxtr in other tissues, such as the gastrointestinal tract, may also be associated with mater-
nal care defects and gastrointestinal motility in rat models [19]. Although the current study
has mainly focused on the hypothalamus and mammary gland, potential connection of the
oxytocin circuitry to the enteric nervous system may also offer some insight into the defects
observed in Peg3-deficient mice.
Materials and methods
Ethics statement
All the experiments related to mice were performed in accordance with National Institutes of
Health guidelines for care and use of animals, and also approved by the Louisiana State Uni-
versity Institutional Animal Care and Use Committee (IACUC), protocol #16–060.
Mouse breeding
In the current study, we used two mutant strains that have been previously characterized: the
OxtrVenus/+ and Peg3CoKO/+ strains [11, 20]. Female heterozygotes for OxtrVenus/+ were crossed
with male heterozygotes for Peg3CoKO/+. The subsequent pups were analyzed in terms of sex,
genotype and weight. For genotyping, genomic DNA was isolated from either clipped ears or
tail snips by incubating the tissues overnight at 55˚C in the lysis buffer (0.1 M Tris-Cl, pH 8.8,
5 mM EDTA, pH 8.0, 0.2% SDS, 0.2 M NaCl, 20 μg/ml Proteinase K). The isolated DNA was
subsequently genotyped using the following two sets of primers: for the OxtrVenus/+ strain,
Primer F (5’-GTTGGGAACAGCGGTGATTA-3’) and R (5'-GGCTCAGGCTTTCTCTACTT-
3'); for the Peg3CoKO/+ strain, Peg3-5arm (5’-CCCTCAGCAGAGCTGTTTCCTGCC-3’) and
LAR3 (5’-CAACGGGTTCTTCTGTTAGTCC-3’). The sex of the pups was determined
through PCR using the following primer set: mSry-F (5’-GTCCCGTGGTGAGAGGCACAAG-
3’) and mSry-R (5’-GCAGCTCTACTCCAGTCTTGCC-3’).
Chromatin ImmunoPrecipitation (ChIP)
Chromatins were prepared from MEF and adult brains, according to the method previously
described [6]. In brief, the homogenized samples were first cross-linked with 1% formaldehyde
for 20 minutes, and then lysed with buffer containing protease inhibitor cocktail (Cat. No.
539131, Millipore). The subsequent nuclei were fractionated with sonication to derive a pool
of DNA fragments size-ranging from 300 to 500 bp in length. The prepared chromatin was
immunoprecipitated with a commercial anti-PEG3 antibody (Cat. No. ab99252, abcam). The
immunoprecipitated DNA was dissolved in 100 μl of TE for PCR analyses.
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed using a gel shift assay system kit (Cat. No. E3053, Promega). This series
of assays used mouse brain nuclear extract (Cat. No. 36053, Active Motif). For the competition
assays, competitor oligonucleotide duplexes (1.74 pico mole, 200X) were first incubated with
mouse brain nuclear extract (2.72 μg) at room temperature for 10 minutes. Later, the P32-
labeled Pgm2l1 oligonucleotide duplex probe (8.7 fento mole, 1X) was added and incubated at
Peg3 control on Oxtr
PLOS ONE | https://doi.org/10.1371/journal.pone.0202476 August 14, 2018 9 / 12
room temperature for additional 20 minutes. The reaction mixture was separated on a 5%
TBE gel (Cat. No. 456–5014, Bio-Rad), and exposed to a film for 2 to 6 hours at -80˚C.
Isolation of mammary epithelial cells
Female dams were sacrificed using CO2 asphyxiation at one day postpartum. Mammary glands
were extracted without lymph nodes, and placed in a 50 mL conical tube with 10 mL of
DMEM/F12 1:1 media. The harvested mammary glands were transferred to petri dishes and
minced to a size of ~1 mm3 under a laminar flow hood. The minced tissue was transferred to a
new 50 mL conical tube containing 10 mL of DMEM/F12 1:1 supplemented with Collagenase
(300 U/mL) and Hyaluronidase (100 U/mL), and placed on a 37˚C shaking incubator at 200
RPM for 2 hours. The mixture was spun down at 2000 RPM for 5 minutes, and the subsequent
pellet was recovered from the supernatant containing the lipid layer. The pellet was again
resuspended in 10 mL of HBSS. Red blood and stromal cells were depleted with 3 rounds of
pulse centrifugations at 1500 RPM for 7 seconds. After the three rounds of wash, the final pel-
let was resuspended in 10 mL of HBSS, partitioned into two 5 mL aliquots, and spun down
again at 2000 RPM for 5 minutes. These two fractions were used for RNA isolation and subse-
quent cDNA synthesis.
Quantitative qRT-PCR analyses
Total RNA was isolated from the mammary epithelial cells and the hypothalamus of adult
mice using a commercial kit (Trizol, Invitrogen). The total RNA was reverse-transcribed using
the M-MuLV kit (Invitrogen), and the subsequent cDNA was used as a template for quantita-
tive real-time PCR. This analysis was performed with the iQ SYBR green supermix (Bio-Rad)
using the ViiA™ 7 Real-Time PCR System (Life Technologies). All qRT-PCR reactions were
carried out for 40 cycles under standard PCR conditions. The analyses of the results from
qRT-PCR were described previously [21]. Statistical significance of potential difference of
expression levels of a given gene between two samples was tested with Mann-Whitney U test.
The information regarding individual primer sequences is available through previous studies
[11].
Immunocytochemistry
At one day postpartum, three sets of nursing females with the following genotypes, OxtrVenus/+;
Peg3+/+ (WT) and OxtrVenus/+; Peg3+/CoKO (KO), were anesthetized with Ketamine-Xylazine
(9:1; 100 mg/kg; i.p.) and perfused through the heart with 0.01 M sodium phosphate buffered
saline (PBS; pH 7.2), followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer
(PB; pH 7.2). The brains were extracted and post fixed in the same fixative for overnight. Coro-
nal sections were transected at 40 μm by an automated vibratome (Leica VT1200; Mannheim,
Germany).
To enhance the signal of Venus, immunocytochemical localization of Venus with anti-
green fluorescent protein (GFP) antibody (ab13970; abcam, Cambridge, UK) was conducted
in the brain sections. The free-floating brain slices were incubated with the primary antibodies
against GFP at dilutions of 1:10,000 in PBS containing 0.5% Triton X-100 (PBST) with contin-
uous gentle agitation at 4˚C for overnight. The brain sections were subsequently incubated
with a secondary antibody (goat anti-chicken) conjugated with Alexa Fluor 488 (Jackson
ImmunoResearch, West Grove, PA) at room temperature for 4 hours. The sections were also
incubated with anti-PEG3 at dilutions of 1:10,000 (custom-made antibody, [6]) and monoclo-
nal anti-OT-neurophysin antibody (PS38 provided by H. Gainer, NIH) at 1:500 overnight at
4˚C, and labeled with AffiniPure Goat Anti-Rabbit IgG Alexa Fluor647 and AfiiniPure Goat
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Anti-Mouse IgG DyLight549 respectively (Jackson ImmunoResearch, West Grove, PA) at
1:250 dilution at room temperature for 2–4 hours. The sections were mounted in polyvinyl
alcohol (PVA) with anti-fading agent 1,4-Diazabicyclo[2.2.2]octane (DABCO) that consists of
4.8 g PVA, 12 g glycerol, 12 ml dH2O, 24 ml 0.2 M Tris-HCl, and 1.25 g DABCO. Fluorescence
microscopic images (1280 x 1024) were acquired digitally (Eclipse 80i equipped with
DS-QiMc, Nikon, Tokyo, Japan).
Supporting information
S1 File. PEG3’s ChIP-seq profile in the 20-kb genomic region surrounding the Oxt and
Avp loci. This file contains the image showing the Peg3 ChIP-seq results as bigwig files as
tracks below the 20-kb genomic region harboring the Oxt and Avp genes.
(PPTX)
S2 File. Oxtr expression within the hypothalamus between WT and KO. This file contains a
set of images showing the ectopic expression of Oxtr in the medial preoptic area of the hypo-
thalamus, which is separate from those presented in Fig 5.
(PPTX)
S3 File. Oxt expression in the SON and PVN of WT and KO. This file contains a set of
images comparing the expression of Oxtr and Oxt within the PVN and SON areas between the
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